Literature DB >> 1613191

Pulmonary and haemodynamic effects of extracorporeal circulation in the cat and the beneficial effects of prostacyclin.

J Jahr1, P O Grände.   

Abstract

Side-effects of a veno-venous extracorporeal system and possible beneficial effects of prostacyclin (epoprostenol) are analyzed on the cat. Three groups were studied; one control group without extracorporeal circulation and two groups with an extracorporeal flow of 10-12 ml/kg/min, one of which was given prostacyclin (70-110 ng/kg/min). The extracorporeal circulation triggered a decrease in arterial saturation (from 99 to 91%) and carbon dioxide elimination (increase in arterial to end-tidal PCO2 by about 1 kpa) a metabolic acidosis (pH approximately 7.20), a platelet consumption (approximately 50%) and shortened survival time, side-effects reduced by prostacyclin. Further, there was a marked increase in haemoglobin concentration indicating hypovolemia via capillary fluid filtration. None of these side-effects were seen in the control group. Extracorporeal circulation as a trigger for pulmonary dysfunction and for impaired tissue nutrition with possible beneficial effects of prostacyclin is discussed, and also form a clinical point of view (i.e. extracorporeal lung assistance, ECLA), on the basis of the results.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1613191     DOI: 10.1007/bf01705045

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  27 in total

1.  Dynamic pulmonary accumulation of labelled neutrophils by blood membrane contact in the pig.

Authors:  L Mårtensson; S Blomqvist; J Jahr; J Thörne
Journal:  Nephron       Date:  1990       Impact factor: 2.847

2.  Haemolysis caused by tubing in extracorporeal circulation.

Authors:  J W STEWART; M F STURRIDGE
Journal:  Lancet       Date:  1959-02-14       Impact factor: 79.321

3.  A critical study of some methods used in investigations on the blood circulation.

Authors:  B FOLKOW
Journal:  Acta Physiol Scand       Date:  1952

4.  Hemolysis during perfusion. Sources and means of reduction.

Authors:  J J OSBORN; K COHN; M HAIT; A SALEL; G HARKINS; F GERBODE
Journal:  J Thorac Cardiovasc Surg       Date:  1962-04       Impact factor: 5.209

5.  Pulmonary injury secondary to extracorporeal circulation. An ultrastructural study.

Authors:  N B Ratliff; W G Young; D B Hackel; E Mikat; J W Wilson
Journal:  J Thorac Cardiovasc Surg       Date:  1973-03       Impact factor: 5.209

Review 6.  On the mechanism of cytoprotection by prostaglandins.

Authors:  A Robert
Journal:  Ann Clin Res       Date:  1984

7.  Prostacyclin but not phentolamine increases oxygen consumption and skin microvascular blood flow in patients with sepsis and respiratory failure.

Authors:  J F Pittet; J S Lacroix; K Gunning; M C Laverriere; D R Morel; P M Suter
Journal:  Chest       Date:  1990-12       Impact factor: 9.410

8.  The importance of microembolism in the pathogenesis of organ dysfunction caused by prolonged use of the pump oxygenator.

Authors:  D B Allardyce; S H Yoshida; P G Ashmore
Journal:  J Thorac Cardiovasc Surg       Date:  1966-11       Impact factor: 5.209

9.  The effect of prostacyclin on the adhesion of leucocytes to injured vascular endothelium.

Authors:  G Jones; J V Hurley
Journal:  J Pathol       Date:  1984-01       Impact factor: 7.996

10.  Beneficial actions of prostacyclin in traumatic shock.

Authors:  A M Lefer; S L Sollott; M J Galvin
Journal:  Prostaglandins       Date:  1979-05
View more
  2 in total

1.  Inhaled nitric oxide in acute respiratory failure: dose-response curves.

Authors:  L Puybasset; J J Rouby; E Mourgeon; T E Stewart; P Cluzel; M Arthaud; P Poète; L Bodin; A M Korinek; P Viars
Journal:  Intensive Care Med       Date:  1994-05       Impact factor: 17.440

2.  Inhaled nitric oxide in acute respiratory distress syndrome with and without septic shock requiring norepinephrine administration: a dose-response study.

Authors: 
Journal:  Crit Care       Date:  1997       Impact factor: 9.097

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.